Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Chen, Xi ^a   Wang, Xu ^a   He, Hua ^a   Liu, Ziling ^a   Hu, Ji Fan ^a,b   Li, Wei ^a  

^a JILIN UNIVERSITY   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABAGOVOMAB; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; KI 67 ANTIGEN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TUMOR INVASION; TUMOR VOLUME; AGED; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; TUMOR EMBOLISM; X-RAY COMPUTED TOMOGRAPHY;

AGED; BIOMARKERS, TUMOR; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84930639642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126276     Document Type: Article

References (38)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-2917. doi: 10.1002/ijc.25516 PMID: 21351269
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300. doi: 10.3322/caac.20073 PMID: 20610543
3. Kosacka M, Jankowska R. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer. Pol Arch Med Wewn. 2009;119:33-37. PMID: 19341176
4. Dabrowska M, Grubek-Jaworska H, Domagala-Kulawik J, Bartoszewicz Z, Kondracka A, Krenke R, et al. Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer. Pol Arch Med Wewn. 2004;111:659-665. PMID: 15508787
5. Cedrés S, Nuñez I, Longo M, Martinez P, Checa E, Torrejón D, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2011;12:172-179. doi: 10.1016/j.cllc.2011.03.019 PMID: 21663860
6. Mino N, Iio A, Hamamoto K. Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs. Cancer. 1988;62:730-734. PMID: 2840187
7. Barlesi F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med. 2004;98:357-362. PMID: 15080079
8. Niklinski J, Furman M, Laudanski J, Kozlowski M. Evaluation of squamous cell carcinoma antigen (SCC-Ag) in the diagnosis and follow-up of patients with non-small cell lung carcinoma. Neoplasma. 1992;39:279-282. PMID: 1331826
9. Palermo F, Carniato A, Fede A, Boccaletto F, Marchiori C. Serum SCC-Ag in head and neck squamous cell carcinoma. Int J Biol Markers. 1990;5:118-120. PMID: 2286775
10. Sanchez De Cos J, Masa F, de la Cruz JL, Disdier C, Vergara C. Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. Chest. 1994;105:773-776. PMID: 8131539
11. Yu D, Du K, Liu T, Chen G. Prognostic Value of Tumor Markers, NSE, CA125 and SCC, in Operable NSCLC Patients. Int J Mol Sci. 2013;14:11145-11156. doi: 10.3390/ijms140611145 PMID: 23712355
12. Moro D, Villemain D, Vuillez JP, Delord CA, Brambilla C. CEA, CYFRA21-1 and SCC in non-small cell lung cancer. Lung Cancer. 1995;13:169-176. PMID: 8581396
13. Schneider J, Bitterlich N, Velcovsky HG, Morr H, Katz N, Eigenbrodt E. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Int J Clin Oncol. 2002;7:145-151. PMID: 12109515
14. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol. 2003;24:209-218. PMID: 14654716
15. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556-1563. doi: 10.1200/JCO.2010.28.7045 PMID: 21422424
16. Hofman V, Ilie MI, Long E, Selva E, Bonnetaud C, Molina T, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129:1651-1660. doi: 10.1002/ijc.25819 PMID: 21128227
17. Yamashita J, Matsuo A, Kurusu Y, Saishoji T, Hayashi N, Ogawa M. Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study. J Thorac Cardiovasc Surg. 2002;124:299-305. PMID: 12167790
18. Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH, Kim CW. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer. 2011;71:209-216. doi: 10.1016/j.lungcan. 2010.04.017 PMID: 20471712
19. Juan O, Vidal J, Gisbert R, Muñoz J, Maciá S, Gómez-Codina J. Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine. Clin Transl Oncol. 2014;16:637-643. doi: 10.1007/s12094-013-1128-8 PMID: 24217975
20. Wang J, Wang K, Xu J, Huang J, Zhang T. Prognostic significance of circulating tumor cells in nonsmallcell lung cancer patients: a meta-analysis. PLoS One. 2013;8:e78070. doi: 10.1371/journal. pone.0078070 PMID: 24223761
21. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009;15:6980-6986. doi: 10.1158/1078-0432. CCR-09-1095 PMID: 19887487
22. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10:6897-6904. PMID: 15501967
23. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706-714. PMID: 17762336
24. Han B, Lin S, Yu LJ, Wang RZ, Wang YY. Correlation of (1) (8) F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer. Nucl Med Commun. 2009;30:831-837. doi: 10.1097/MNM.0b013e32832dcfc4 PMID: 19734817
25. Thunnissen FB, Schuurbiers OC, den Bakker MA. A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology. 2006;48:779-786. PMID: 16722925
26. Soomro IN, Holmes J, Whimster WF. Predicting prognosis in lung cancer: use of proliferation marker, Ki67 monoclonal antibody. J Pak Med Assoc. 1998;48:66-69. PMID: 9783030
27. Sun Z, Aubry MC, Deschamps C, Marks RS, Okuno SH, Williams BA, et al. Histologic grade is an independent prognostic factor for survival in non-small cell lung cancer: an analysis of 5018 hospital- and 712 population-based cases. J Thorac Cardiovasc Surg. 2006;131:1014-1020. PMID: 16678584
28. Ou SH, Zell JA, Ziogas A, Anton-Culver H. Prognostic factors for survival of stage I nonsmall cell lung cancer patients: a population-based analysis of 19, 702 stage I patients in the California Cancer Registry from 1989 to 2003. Cancer. 2007;110:1532-1541. PMID: 17702091
29. Kalogeraki A, Tzardi M, Zoras O, Giannikaki E, Papadakis M, Tamiolakis D, et al. Apoptosis and cell proliferation correlated with tumor grade in patients with lung adenocarcinoma. In Vivo. 2010;24:667-670. PMID: 20952731
30. Molnar B, Floro L, Sipos F, Toth B, Sreter L, Tulassay Z. Elevation in peripheral blood circulating tumor cell number correlates with macroscopic progression in UICC stage IV colorectal cancer patients. Dis Markers. 2008;24:141-150. PMID: 18334735
31. Weihrauch MR, Skibowski E, Koslowsky TC, Voiss W, Re D, Kuhn-Regnier F, et al. Immunomagnetic enrichment and detection of micrometastases in colorectal cancer: correlation with established clinical parameters. J Clin Oncol. 2002;20:4338-4343. PMID: 12409333
32. Weckermann D, Muller P, Wawroschek F, Krawczak G, Riethmuller G, Schlimok G. Micrometastases of bone marrow in localized prostate cancer: correlation with established risk factors. J Clin Oncol. 1999;17:3438-3443. PMID: 10550139
33. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA Jr, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 2005;27:49-57. PMID: 15942643
34. Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ, et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer. 2010;126:669-683. doi: 10.1002/ijc.24814 PMID: 19662651
35. Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res. 2008;14:5013-5021. doi: 10.1158/1078-0432. CCR-07-5125 PMID: 18698019
36. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res. 2014;20:2553-68. doi: 10.1158/1078-0432. CCR-13-2664 PMID: 24831278
37. Wang B, He YJ, Tian YX, Yang RN, Zhu YR, Qiu H. Clinical Utility of Haptoglobin in Combination with CEA, NSE and CYFRA21-1 for Diagnosis of Lung Cancer. Asian Pac J Cancer Prev. 2014;15:9611-4. PMID: 25520076
38. Yu Z, Chen XZ, Cui LH, Si HZ, Lu HJ, Liu SH. Prediction of lung cancer based on serum biomarkers by gene expression programming methods. Asian Pac J Cancer Prev. 2014;15:9367-73. PMID: 25422226